TCIM
RCUS icon

TIAA CREF Investment Management’s Arcus Biosciences RCUS Stock Holding History

TIAA CREF Investment Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$786K Buy
62,911
+2,306
+4% +$25K ﹤0.01% 2421
2018
Q4 		$653K Buy
+60,605
New +$707K ﹤0.01% 2464

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TIAA CREF Investment Management's RCUS Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Arcus Biosciences (RCUS) stake by 3.8% in Q1 2019, buying an estimated $25K and bringing the position to 62,911 shares worth $786K. The position accounts for ﹤0.01% of the portfolio, ranked #2421.

TIAA CREF Investment Management first reported a position in RCUS in Q4 2018 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold RCUS as of Q1 2019.

  • TIAA CREF Investment Management held 62,911 shares of Arcus Biosciences worth $786K as of Q1 2019.
  • TIAA CREF Investment Management bought 2,306 Arcus Biosciences shares in Q1 2019, an estimated $25K.
  • Arcus Biosciences made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2421 holding.
  • TIAA CREF Investment Management first reported a position in Arcus Biosciences in Q4 2018 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.